Literature DB >> 31260261

Considerably Lower Levels of Hypocretin-1 in Cerebrospinal Fluid Is Revealed by a Novel Mass Spectrometry Method Compared with Standard Radioimmunoassay.

Kjetil Bårdsen1,2, Michaela D Gjerstad3,4, Markku Partinen5, Ingeborg Kvivik1, Anne Bolette Tjensvoll4, Peter Ruoff6, Roald Omdal7,8, Cato Brede9,2.   

Abstract

Low levels of hypocretin-1 (Hcrt1) in cerebrospinal fluid (CSF) are associated with narcolepsy type 1 (NT1). Although immunoassays are prone to antibody batch differences, detection methods and variation between laboratories, the standard method for Hcrt1 measurement is a radioimmunoassay (RIA). Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is an antibody- and radioactive free alternative for precise measurement of Hcrt1. We developed an LC-MS/MS method for measurement of Hcrt1 in CSF with automated sample preparation by solid-phase extraction (SPE). The LC-MS/MS method was compared with the RIA method for Hcrt1 detection. CSF samples from healthy subjects and NT1 patients was obtained by lumbar puncture. NT1 patients were diagnosed according to the minimal criteria by the International Classification of Sleep Disorders (ICSD). The LC-MS/MS method showed linearity across the range of calibrators and had a limit of detection (LOD) of 2.5 pg/mL and a limit of quantitation (LOQ) of 3.6 pg/mL. Comparison of the LC-MS/MS method with RIA revealed a 19 times lower level in healthy controls and 22 times lower level in NT1 patients with the LC-MS/MS method than with RIA. Bland-Altman analysis demonstrated agreement between the methods. These results question what is detected by RIA and strongly suggest that the physiological concentrations of the peptide are much lower than previously believed. LC-MS/MS proves to be an alternative for detection of Hcrt1 for diagnosis of narcolepsy.

Entities:  

Year:  2019        PMID: 31260261     DOI: 10.1021/acs.analchem.9b02710

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  6 in total

Review 1.  Recent advances in mass spectrometry analysis of neuropeptides.

Authors:  Ashley Phetsanthad; Nhu Q Vu; Qing Yu; Amanda R Buchberger; Zhengwei Chen; Caitlin Keller; Lingjun Li
Journal:  Mass Spectrom Rev       Date:  2021-09-24       Impact factor: 9.011

2.  Plasma Orexin-A Levels in Patients With Schizophrenia: A Systematic Review and Meta-Analysis.

Authors:  Shaoli Li; Ruili Zhang; Shaohua Hu; Jianbo Lai
Journal:  Front Psychiatry       Date:  2022-05-25       Impact factor: 5.435

3.  Misdiagnosis of narcolepsy caused by a false-positive orexin-A/hypocretin-1 enzyme immune assay.

Authors:  Tomi Sarkanen; Gabriele Sved; Maria Juujärvi; Anniina Alakuijala; Markku Partinen
Journal:  J Clin Sleep Med       Date:  2022-08-01       Impact factor: 4.324

4.  Orexin 2 receptor (OX2R) protein distribution measured by autoradiography using radiolabeled OX2R-selective antagonist EMPA in rodent brain and peripheral tissues.

Authors:  Kayo Mitsukawa; Haruhide Kimura
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

5.  Hypocretin-1 measurements in cerebrospinal fluid using radioimmunoassay: within and between assay reliability and limit of quantification.

Authors:  Adrienne Elisabeth van der Hoeven; Kevin van Waaij; Denise Bijlenga; Frederik Willem Cornelis Roelandse; Sebastiaan Overeem; Jaap Adriaan Bakker; Rolf Fronczek; Gert Jan Lammers
Journal:  Sleep       Date:  2022-07-11       Impact factor: 6.313

6.  Cerebrospinal fluid orexin in Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Spencer P Treu; David T Plante
Journal:  Sleep Med       Date:  2021-07-13       Impact factor: 4.842

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.